FR3079414B1 - Composition comprenant un agoniste du recepteur du glp-2 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes - Google Patents

Composition comprenant un agoniste du recepteur du glp-2 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes Download PDF

Info

Publication number
FR3079414B1
FR3079414B1 FR1852661A FR1852661A FR3079414B1 FR 3079414 B1 FR3079414 B1 FR 3079414B1 FR 1852661 A FR1852661 A FR 1852661A FR 1852661 A FR1852661 A FR 1852661A FR 3079414 B1 FR3079414 B1 FR 3079414B1
Authority
FR
France
Prior art keywords
glp
receptor agonist
composition
polyaminoacid
carrying carboxylate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1852661A
Other languages
English (en)
Other versions
FR3079414A1 (fr
Inventor
Remi Soula
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adocia SAS
Original Assignee
Adocia SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adocia SAS filed Critical Adocia SAS
Priority to FR1852661A priority Critical patent/FR3079414B1/fr
Priority to PCT/EP2018/079912 priority patent/WO2019086559A1/fr
Publication of FR3079414A1 publication Critical patent/FR3079414A1/fr
Application granted granted Critical
Publication of FR3079414B1 publication Critical patent/FR3079414B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

[0001] L'invention concerne une composition stable physiquement sous forme d'une solution aqueuse injectable, dont le pH est compris entre 6,0 et 8,0, comprenant au moins : a) un agoniste du récepteur du GLP-2 ou un analogue du GLP-2, ou h[Gly2]GLP-2, et b) un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes Hy, ledit co-polyaminoacide étant constitué d'unités glutamiques ou aspartiques et lesdits radicaux hydrophobes Hy.
FR1852661A 2017-10-31 2018-03-27 Composition comprenant un agoniste du recepteur du glp-2 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes Expired - Fee Related FR3079414B1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FR1852661A FR3079414B1 (fr) 2018-03-27 2018-03-27 Composition comprenant un agoniste du recepteur du glp-2 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
PCT/EP2018/079912 WO2019086559A1 (fr) 2017-10-31 2018-10-31 Composition comprenant un agoniste du recepteur du glp-2 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1852661A FR3079414B1 (fr) 2018-03-27 2018-03-27 Composition comprenant un agoniste du recepteur du glp-2 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
FR1852661 2018-03-27

Publications (2)

Publication Number Publication Date
FR3079414A1 FR3079414A1 (fr) 2019-10-04
FR3079414B1 true FR3079414B1 (fr) 2020-05-01

Family

ID=63080017

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1852661A Expired - Fee Related FR3079414B1 (fr) 2017-10-31 2018-03-27 Composition comprenant un agoniste du recepteur du glp-2 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes

Country Status (1)

Country Link
FR (1) FR3079414B1 (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9905416D0 (en) * 1999-03-09 1999-05-05 Allelix Biopharma Small molecules having GLP-2 like activity
GB9930882D0 (en) * 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
EP2814461B1 (fr) * 2012-01-09 2019-07-24 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide substitue
WO2014096440A2 (fr) * 2012-12-21 2014-06-26 Novozymes Biopharma Dk A/S Composition
FR3052071B1 (fr) * 2016-06-07 2018-09-07 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon et un co-polyaminoacide

Also Published As

Publication number Publication date
FR3079414A1 (fr) 2019-10-04

Similar Documents

Publication Publication Date Title
FR3001896B1 (fr) Solution injectable a ph 7 comprenant au moins une insuline basale dont le point isolectrique est compris entre 5,8 et 8,5 et un polymere anionique hydrophobise
GT200600038A (es) Agonistas de pyy y sus usos
SA518400596B1 (ar) محلول قابل للحقن عند الرقم الهيدروجيني 7 يشتمل على أنسولين قاعدي واحد على الأقل تتراوح نقطة (pi) التعادل الكهربائي الخاصة به من 5.8 إلى 8.5، و/أو أنسولين وجبات و/أو هرمون قناة هضمية، وحمض بولي أميني
WO2019110797A8 (fr) Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
FR3001895B1 (fr) Solution injectable a ph7 comprenant au moins une insuline basale dont le point isoelectrique est compris en 5,8 et 8,5 et un compose anionique porteur de charges carboxylates et de radicaux hydrophobes
SG11201810901VA (en) Compositions in the form of an injectable aqueous solution, comprising human glucagon and a statistical copolyamino acid
EA201892156A1 (ru) Система доставки
EA201190295A1 (ru) Композиции для дермальной доставки, содержащие комплексы активного агента с частицами фосфата кальция, и способы их применения
PH12020550804A1 (en) Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a copolyamino acid
MA51600A (fr) Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
BR112018014277A2 (pt) formulação, e, método de preparação de uma solução injetável de um axl-adc
RS20080471A (en) Preparing of a pharmaceutical preparation for the treatment of fibrosis using an antagonist of the integrin alpha-4-subunit
FR3079414B1 (fr) Composition comprenant un agoniste du recepteur du glp-2 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
FR3072875B1 (fr) Composition comprenant un agoniste du recepteur du glp-2 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
FR3084584B1 (fr) Solution injectable a ph 7 comprenant du glucagon humain et un compose amphiphile porteur de radicaux hydrophobes
FR3061023B1 (fr) Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
FR3074682B1 (fr) Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
FR3074680B1 (fr) Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
FR3083085B1 (fr) Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
FR3074683B1 (fr) Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide
FR3013607B1 (fr) Composition d'encre a base de nanoparticules
MX2019009992A (es) Sistema desplegable de medicion de limitacion del ancho de via en base a vehiculos ferroviarios.
FR3061660B1 (fr) Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide
FR3074681B1 (fr) Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
BRPI0416427A (pt) suspensão aquosa e método de preparação de suspensão aquosa

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20191004

PLFP Fee payment

Year of fee payment: 3

ST Notification of lapse

Effective date: 20211105